APONTIS PHARMA Logo

APONTIS PHARMA builds on strong position and profitability in first half of 2021 – preliminary figures and forecast confirmed

Monheim am Rhein, 11 August 2021. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, has expanded its unique positioning, revenue growth and market leadership in the Single Pills segment in a successful first half of 2021 and is thus directly on track to meet the forecast for the current financial year communicated in connection with the IPO.
APONTIS PHARMA grew in the 6-month period of 2021 against the general market trend in the pharmaceutical industry by posting a 36% increase in revenue to EUR 24.0 million. Single Pill revenues were the main growth drivers with a significant increase of 83% to EUR 14.0 million and increased the share of Single Pills in total revenues to 58% (H1 2020: 43%). Cost of materials increased significantly slower than the revenues volume. Earnings before interest, taxes, depreciation and amortization (EBITDA adjusted), which are mainly adjusted for IPO costs, improved at Group level by EUR 4.3 million to EUR 2.8 million (H1 2020: negative).
APONTIS PHARMA has a solid asset and financial position with an equity ratio of 72%, liquid assets of EUR 30.5 million and liabilities of EUR 7.6 million.
For financial year 2021, the Management Board continues to expect revenues of EUR 48.5 million and EBITDA adjusted of EUR 5.5 million.
Karlheinz Gast, CEO of APONTIS PHARMA AG: “Our focus on Single Pills has enabled us to achieve significant progress. Our financial results in the first half of the year underscore that going public in the spring of 2021 was the right move to further strengthen and expand our position as ‘The Single Pill Company’ in the best possible way with the proceeds from the issuance of new shares. We are convinced that upcoming launches of innovative Single Pills from the near-term development pipeline will contribute to the target. Having already paid back our debt, we intend to use further proceeds raised in the IPO for targeted investments, in particular in the development of new Single Pills, the acceleration of development and licensing of the current near-term product pipeline as well as the expansion of marketing and sales activities to gain further market share.”
Unaudited Group figures H1 2021
in EUR million H1 2021 H1 2020 ∆
Single Pill revenues 14.0 7.7 83.2%

Total revenues 24.0 17.7 35.9%
EBITDA adjusted 2.8 -1.4 4.3
EBITDA margin adjusted (in %) 11.8 -8.1 n/a
APONTIS PHARMA AG’s 2021 half-year report is available on the company’s website at ir.apontis-pharma.de.
Webcast/Phone Conference:
CEO Karlheinz Gast and CPO Thomas Milz will explain the results of the first half of 2021 in a webcast presentation today, 11 August 2021, 14.00 CEST. The presentation will be held in English.
Please register in time to participate at:
APONTIS PHARMA Half Year Report 2021 – Webcast/Teleconference.
The accompanying presentation will also be available on the company’s website prior to the start.
About APONTIS PHARMA:
APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three patent-free active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases as well as diabetes and respiratory diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. Driven by the more effective therapeutic success demonstrated in the START study, APONTIS PHARMA’s focus has been on Single Pills since October 2020. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe’s leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.
APONTIS PHARMA AG
Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de
APONTIS PHARMA Presse Contact
CROSS ALLIANCE communication GmbH
Sven Pauly
Sara Pinto
ir@apontis-pharma.de
T: +49 89 125 09 0330

Linda Lenz

"Creativity and perfection are not mutually exclusive, but complementary."

IR Consultant at CROSS ALLIANCE since 2021.
Linda Lenz’s core competencies are public and influencer relations as well as project management.
With a a M.Sc. degree in Strategic Communication and PR and a B.A. in English Studies and Communication and Media Studies, she is fully committed to her clients because she always insists on doing the job right.
4 years of experience in Public Relations and Influencer Relations expertise in the Automotive and Energy Special Supporter ESG industries.

Jens Jüttner

"Designing a customised communication strategy for clients is what drives me. Their success is my reward."

Jens Jüttner has extensive experience in news and business journalism across all presentation formats and channels. As an investor relations consultant, he devotes his energies to the regular communications of listed companies and also provides support with their media relations activities.

Senior Consultant at CROSS ALLIANCE since 2018
BA in Journalism / Banking Officer
Five years as a member of the editorial team of business and investor magazine FOCUS-MONEY
Three years as Head of Department for “Week”
Extensive experience in writing advertorials
Shortlisted for the Alternative Media Prize 2013
Social Media Manager (Chambers of Industry and Commerce) – final project: Development of a hybrid social media campaign for LinkedIn and Twitter for an IR and media agency

T: +49 89 125 09 03 32

Markus Horntrich

"My maxim to ensure optimum performance on all your communications issues: Get up early, give it your all and work hard."

Markus Horntrich is a stock market enthusiast and, as a former editor-in-chief, has extensive experience in financial journalism and a broad network, which he uses as a basis for all aspects of PR/IR communication.

Economics graduate

Self-employed PR/IR consultant and Senior Consultant at CROSS ALLIANCE
Author
19 years at investor magazine DER AKTIONÄR
8 years as editor-in-chief at DER AKTIONÄR

T: +49 89 125 09 03 30
M: +49 170 321 42 26

Michael Lang

"As a former editor-in-chief and full-blooded journalist, a matter particularly close to my heart is ensuring that our clients get noticed in just the right way in the media."

As an experienced business journalist, Michael Lang uses his extensive network in the financial community to give clients the best media relations.

Partner at CROSS ALLIANCE since 2013
Self-employed professional in investor relations since 2010
Head of IR at IBS AG (Prime Standard) for four years
Ten years as a member of the editorial team of financial magazine DER AKTIONÄR (“2010 award for investor magazine of the year”), acting as editor-in-chief and deputy editor-in-chief, in both positions for three years
15 years of experience in financial journalism
Degree in Business Mathematics, Bayreuth University

T: +49 89 125 09 03 34

Susan Hoffmeister

"I support every company with communication just as I do my own. That's my biggest motivation."

Managing Partner Susan Hoffmeister supports listed companies with their investor relations.

Founder & Managing Director of CROSS ALLIANCE communication GmbH
Degree in Business Administration, BA in Finance & Accounting, MBA
Self-employed entrepreneur in investor relations since 2006
Deutsche Börse qualified Supervisory Board member since 2017
Member of the Supervisory Board of LEHNER INVESTMENTS AG
Head of Corporate Communications at Siemens London for five years
Head of IR at various listed companies in the software and IT industry for six years

Extensive IPO experience
T: +49 89 125 09 03 33

Sara Pinto

"My motto is 'Create value through communication'. My international professional background helps me to achieve this. I work with clients to get them the best results."

As an investor relations expert and member of the Cross Alliance team, Sara Pinto places particular emphasis on providing her clients with in-depth consultations and on strategic communication. Her specialist area is sustainability.

Consultant at CROSS ALLIANCE since 2019

MA in Business Administration & Management
Five years as Market Research Manager at FOCUS-MONEY

Extensive experience in B2B sales
Expert in CSR and ESG – contact person for sustainability strategy development, implementation of ESG criteria in corporate communications, and sustainability reporting
Language proficiency: Italian (mother tongue), German, English, Spanish

T: +49 89 125 09 03 35

Sven Pauly

"I develop innovative concepts for our clients, which actively contributes to their success."

Investor relations consultant Sven Pauly has extensive experience in TV news production, and specialises in reporting and regular communications for listed companies.

Senior Consultant at CROSS ALLIANCE since 2016
MA in Corporate Communications/PR
Consultant for investor relations and corporate communications
Extensive experience in capital market consultation
Has held roles in designated sponsoring and public affairs
Over ten years of experience in TV news production

T: +49 89 125 09 03 31